Physician profile
Dylan Thaxton
NPI 1609040849
$877.50
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $92.31 · 2021: $38.91 · 2022: $163 · 2023: $399 · 2024: $45.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $188.36 | 2021-2024 | |
| Glaxosmithkline, LLC. | $185.00 | 2020-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $85.68 | 2019-2022 | |
| Amgen INC. | $81.30 | 2019-2023 | Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $76.80 | 2019-2023 | |
| Lilly USA, LLC | $56.91 | 2020-2023 | Mounjaro |
| Dexcom, INC. | $40.79 | 2022-2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $34.12 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Abbvie INC. | $26.83 | 2023 | Vraylar |
| Astellas Pharma US INC | $25.50 | 2023 | Veozah |
| Novo Nordisk INC | $24.95 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.24 | 2024 | Gvoke Hypopen |
| Boston Scientific Corporation | $14.54 | 2019 | |
| Amarin Pharma, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Thaxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.